AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00286221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA fentanyl
Description: PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted
Study NCT00286221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRN fentanyl
Description: IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
Study NCT02616770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1226 (4%)
Description: 3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
Study NCT02616770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (for 4%)
Description: 3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
Study NCT02616770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1226(8%)
Description: 3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
Study NCT02616770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (for 8%)
Description: 3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
Study NCT02616770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1226(12%)
Description: 3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
Study NCT02616770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (for 12%)
Description: 3ml saline nebulized with Medical Air for 2 minutes as a single dose
Study NCT02771626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Glutaminase inhibitor
Study NCT03485820 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Stroke education
Description: The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
Study NCT00651755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: 125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
Study NCT00651755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 By Vein On Day 1
Study NCT00651755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m\^2 By Vein Over 48 Hours On Days 1-2
Study NCT00651755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg By Vein On Day 1
Study NCT00651755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 100 mg PO for 5 Days
Study NCT00651755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 By Vein On Day 1.
Study NCT00651755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: 8 mg daily for 2 days
Study NCT04495127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib 25 mg/m2 BID
Study NCT04289246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Ambient Display (MAD)
Description: MAD was implemented for Android tablets to provide the following external cues:~* Abstract and stylized representations of medication adherence. The MAD shows a virtual birdcage, which has the aim of raising elders' consciousness about how they have to take responsibility for caring for their health, in a way similar to willingly caring for a pet. Each day, a newborn pet grows to represent medication compliance. By touching any point on the parakeet's virtual cage, the MAD presents information on the participants' daily medication compliance.~* Auditory and visual reminders. The parakeet provides auditory reminders (a parakeet whistle) and pictograms to inform the medication to take.~After participants take their medication, they move the MAD closer to the pill container to indicate that the medication was taken. This functionality was implemented through Near Field Communication (NFC) technology. Afterward, the parakeet acknowledges that the medication was registered as taken.
Study NCT01178593 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gut-focused hypnotherapy in group sessions
Description: weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)
Study NCT03921697 — intervention group
Intervention type: DEVICE
Intervention: Werable sensors
Description: Parkinson Disease Patients monitored by werable sensors
Study NCT00620815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine
Description: Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
Study NCT02304263 — intervention group
Intervention type: DRUG
Intervention: iohexol
Description: 5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes
Study NCT03807011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl group
Description: fentanyl 2 μg/kg
Study NCT03807011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil group
Description: remifentanil 0.2 μg/kg/min
Study NCT03604042 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Protein fortifier
Description: Protein Fortifier to be added to Fortified human milk according to feeding regimen
Study NCT03604042 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Protein fortifier
Description: Protein Fortifier to be added to Fortified human milk according to feeding regimen
Study NCT03160742 — intervention group
Intervention type: DEVICE
Intervention: Mespere VENUS 200CVP system
Description: Non-invasive sensor placed on the neck
Study NCT04571710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1258
Description: Drug: SHR1258 400mg
Study NCT04130451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PYODINE AND TALC SLURRY
Description: pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters.~TALC a white, grey, or pale green soft mineral with a greasy feel, occurring as translucent masses or laminae and consisting of hydrated magnesium silicate
Study NCT02183831 — intervention group
Intervention type: DEVICE
Intervention: Insertion of the capsular tension ring
Study NCT03401983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training and Abdominal Training
Description: Pelvic Floor Muscle Training + Abdominal Training program was used in the study. The follow-up measurements of the PFMT+AT group were obtained in the 0th, 4th, and 8th weeks.
Study NCT03401983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training
Description: Pelvic Floor Muscle Training program was used in the study. The follow-up measurements of the PFMT group were obtained in the 0th, 4th, and 8th weeks.
Study NCT02444572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 4000 IU
Study NCT02444572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 4000 IU
Study NCT01946997 — intervention group
Intervention type: OTHER
Intervention: OCT Imaging both Normal and diabetic groups
Description: Images taken to determine thickness values in the retina
Study NCT01976234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh RBC
Description: Patients will receive fresh blood only
Study NCT01976234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Old RBC
Study NCT03616899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 Ophthalmic Suspension
Description: KPI-121 Ophthalmic Suspension
Study NCT03616899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle for KPI-121 0.25% ophthalmic suspension
Study NCT00739037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00739037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZ-417
Study NCT00620815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1
Description: Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
Study NCT00620815 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine
Description: Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
Study NCT00620815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1
Description: Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
Study NCT00620815 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine
Description: Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
Study NCT00620815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine
Description: Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
Study NCT02297620 — intervention group
Intervention type: DRUG
Intervention: Suglat®
Description: oral
Study NCT03474380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iHI-FIVES
Description: Implementation of iHI-FIVES caregiver skills training
Study NCT03807336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-Focused Skills Training for Parents - Experiential
Description: The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
Study NCT03807336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion-Focused Skills Training for Parents - Experiential
Description: The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
Study NCT03807336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-Focused Skills Training for Parents - Psychoeducational
Description: The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
Study NCT03807336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion-Focused Skills Training for Parents - Psychoeducational
Description: The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
Study NCT02828202 — intervention group
Intervention type: OTHER
Intervention: Biological
Description: DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
Study NCT02828202 — intervention group
Intervention type: OTHER
Intervention: Tissular
Description: Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
Study NCT00063089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S. aureus Immune Globulin Intravenous (Human) 5%
Study NCT00063089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S. aureus Immune Globulin Intravenous (Human) 5%
Study NCT00644501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DiaPep277
Description: 1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
Study NCT00937014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard infant formula
Description: Standard infant formula given during the first 9 months of life, as per standard requirement
Study NCT00937014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test formula
Description: Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
Study NCT01056159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol dry powder inhaler
Description: Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
Study NCT01056159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)
Description: Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
Study NCT00082966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
Description: Given IV
Study NCT02311062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric hamstring exercises
Description: Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
Study NCT02311062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unistable exercises
Description: Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
Study NCT02311062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Only soccer training
Study NCT00808496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).~MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported.
Study NCT02828202 — intervention group
Intervention type: OTHER
Intervention: Quality of life
Description: Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
Study NCT01353976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole Nitrate Foam 1%
Description: Econazole Nitrate Foam 1% applied once a day for 4 weeks
Study NCT01353976 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle foam applied once a day for 4 weeks
Study NCT02872090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: inhalation
Study NCT00808496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiography
Description: Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.~Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported.
Study NCT00808496 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
Study NCT01411657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501 CNTF Implant
Description: Single implantation of CNTF-secreting NT-501 device into one eye
Study NCT04511286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Systematic confrontation with stimuli associated with symptom-related distress, to achieve therapeutic changes in cognitions or behavior
Study NCT03142867 — intervention group
Intervention type: OTHER
Intervention: non-applicable
Description: non-applicable
Study NCT00310609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopentetate dimeglumine (Magnevist)
Description: Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
Study NCT02000752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study NCT00295061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP
Description: alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
Study NCT02000752 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham point acupuncture
Study NCT02964793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention group
Description: The intervention will include~1. clinician training sessions, designed to raise awareness of the importance of monitoring for FGR and standardizing SFH measurements~2. the use of SFH charts and EFW customised charts, built with the same software allowing all information to be recorded on an unique document~3. the use of the EFW values mentioned on US report, to plot EFW on the customised chart~4. and explicit recommendations about interpretation of longitudinal values of SFH and EFW measurements. If slopes through consecutive plots are not parallel to either of the predicted centile lines (90th, 50th, 10th) on the chart, and either of the centile lines are 'crossed', fetal biometry by ultrasound scan will be recommended.
Study NCT03360617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syringe IV Push over 2-3 minutes
Description: IV antibiotics will be administered by Syringe IV Push over 2-3 minutes
Study NCT03360617 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Piggyback over 30 minutes
Description: IV antibiotics will be administered by IV Piggyback over 30 minutes.
Study NCT02731066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard pro
Description: Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
Study NCT00295061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha-1 proteinase inhibitor (human)
Description: Prolastin
Study NCT02731066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High pro
Description: Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.
Study NCT02731066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carbo bev
Description: During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing \~1.8 g carbohydrate/min.
Study NCT02731066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo bev
Description: During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
Study NCT00486304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADD
Description: The ADD has a composition of 65% carbohydrate, 20% fat, and 15% protein. The diet will be completely depleted of vitamins A, E and beta-carotene; it will have 10 mg of vitamin C (6.5% of RDA) added per person per day
Study NCT00486304 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Jevity 1.5 (1.5 cal/mL) will be used for the placebo patients in this study. This will simulate the standard of care for patients not on the ADD. Jevity 1.5 is an isotonic, fiber-fortified, high-nitrogen liquid formula providing complete, balanced nutrition for patients requiring short- or long-term tube feeding, given once per day
Study NCT02734706 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LRC™ capsule
Description: Twice per day (BID), 9 weeks
Study NCT02734706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Twice per day (BID), 9 weeks
Study NCT00413881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WAVEFRONT- GUIDED LASIK ENHANCEMENT
Description: Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system
Study NCT00413881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL LASIK ENHANCEMENT
Description: Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.